Abstract library

2227 results for "colorectal neuroendocrine tumors".
#1473 Long-term Outcomes of Colorectal Neuroendocrine Tumors: A Sub Group Analysis of 29 G3 Cases According to the 2010 WHO Classification
Introduction: Colorectal neuroendocrine tumors (NETs) are a group of heterogenous neoplasm.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Jiahua Leng
Authors: Leng J, Li Z W, Li Y, Chen Z S, ...
#1270 Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms in China
Introduction: Limited research is available regarding colorectal neuroendocrine neoplasms (NENs), especially in China.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Mengjie Jiang
Authors: Jiang M, Fu J, Tan Y, Hu H, ...
#2074 The Risk of Secondary Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Tumors – A Nationwide Population Based Study
Introduction: It has been suggested that secondary primary colorectal adenocarcinomas (SPCA) occur more often than normal in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Student Tobias Stemann Lau
#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Kosmas Daskalakis
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...
#1054 Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Hepatic arterial embolization with 90Y-labelled microspheres is a method of delivering radioactivity to liver tumors, that has been used to treat primary hepatocellular carcinomas and liver metastases from colorectal carcinomas and neuroendocrine tumors.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Associate Prof Dan Granberg
#635 Neuroendocrine Tumors of the Gastrointestinal Tract with Second Primary Malignancy
Introduction: Neuroendocrine tumors of the gastrointestinal tract (NETs of GIT) are rare neoplasms frequently associated with synchronous or metachronous second primary malignancy (SPM). This phenomenon can be a result of an increasing incidence of NETs in patients who are examined for another primary malignancy. However, other theories suppose genetic predispositions or growth impact of different neuroendocrine peptides produced by NET.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MUDr., PhD. Katarina Machalekova
Authors: Machalekova K, Kajo K, Kajo M, ...
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#2804 Claudin-18 Is a Sensitive and a Specific Marker for Gastric Neuroendocrine Tumors
Introduction: Antibody-based cancer therapies are emerging as promising therapeutics in oncology, including one in clinical trials that targets claudin-18, a protein expressed in normal gastric epithelium and some gastric adenocarcinoma. We currently have no markers for gastric well-differentiated neuroendocrine tumors (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Housestaff Mary Wong
Authors: Wong M, Huynh C, Kim S, Dhall D, ...
#2879 Lung Neuroendocrine Tumors: Experience of Medical Oncology Department of Hospital 1st November 1954 Oran
Introduction: Lung neuroendocrine tumors account for 25% of all neuroendocrine tumors. It is a heterogeneous group that meets morphological criteria; immunohistochemical and molecular; defining 4 groups: Typical and atypical carcinoid tumors, neuroendocrine carcinomas with large cell and small cells. Carcinoid syndrome is rare in these tumors and the treatment is based on surgery for localized forms and multimodal treatment for metastatic forms.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Hakima Kehili